Open an Account
search icon
3
NOTIFICATIONS
Best Algo trading app in India
Bigul

Board Meeting Intimation for To Consider And Approve The Un-Audited Standalone And Consolidated Financial Results Of The Company For The Quarter Ended On June 30, 2018 Along With Any Other Business, If Any.

 LINCOLN PHARMACEUTICALS LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 14/08/2018 ,inter alias, to consider and approve We would like to inform that the Meeting of the Board of Directors of the Company is scheduled to be held on Tuesday, August 14, 2018 at the Registered Office of the Company inter-alia to consider and approve the Un-Audited Standalone and Consolidated Financial Results of the Company...
04-08-2018
Bigul

Shareholding for the Period Ended June 30, 2018

 Lincoln Pharmaceuticals Ltd has submitted to BSE the Shareholding Pattern for the Period Ended June 30, 2018. For more details, kindly Click here
18-07-2018
Bigul

Statement Of Investor Complaints For The Quarter Ended June 2018

 No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0110 Name of the Signatory :- MAHENDRA G. PATELDesignation :- Director
14-07-2018
Bigul

Intimation Under Regulation 33 (3) (B) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015.

 Pursuant to Regulation 33 (3) (b) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform that the Company will continue to submit Quarterly /Year to Date Standalone and Consolidated Financial Results for the Financial Year 2018-19.
21-06-2018
Bigul

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kailashben Mahendrabhai Patel
11-06-2018
Bigul

Announcement Under Regulation 30 Of SEBI (LODR) Regulations, 2015

 It to be informed that Effective from June 8, 2018, Shri Rajnikant G. Patel [DIN: 00104786] will act as a Non-Executive Director [Promoter Category] of the Company.
08-06-2018
Bigul

Annual report for Lincoln Pharmaceuticals Ltd. for FY-2018
31-05-2018
Bigul

Corporate Action-Board approves Dividend

 The Board of Directors of the Company at their meeting held today, i.e. on May 30, 2018 had considered and Recommended the Dividend of Rs. 1.50/- (@ 15%) Per Share of Face Value of Rs. 10/- Each of the Company, subject to the approval of Shareholders at the Ensuring Annual General Meeting.
30-05-2018
Bigul

Results-Financial Results For March 31, 2018

 The Board of Directors of the Company at their meeting held today, i.e. on May 30, 2018 had considered following: 1. Approved the Audited Consolidated and Standalone Financial Results along with Statement of Assets and Liabilities of the Company for the Quarter and Year Ended on March 31, 2018. 2. Auditors'' Report on Audited Consolidated and Standalone Financial Results for the aforesaid period received from M/s. J. T. Shah & Co., Statutory Auditors of the Company....
30-05-2018
Bigul

Board Meeting-Outcome of Board Meeting

 The Board of Directors of the Company at their meeting held today, i.e. on May 30, 2018 had considered following: 1. Approved the Audited Consolidated and Standalone Financial Results along with Statement of Assets and Liabilities of the Company for the Quarter and Year Ended on March 31, 2018. 2. Auditors' Report on Audited Consolidated and Standalone Financial Results for the aforesaid period received from M/s. J. T. Shah & Co., Statutory Auditors of the Company....
30-05-2018
Next Page
Close

Let's Open Free Demat Account